These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 26411412)

  • 21. Cytochrome P450: Polymorphisms and Roles in Cancer, Diabetes and Atherosclerosis.
    Elfaki I; Mir R; Almutairi FM; Duhier FMA
    Asian Pac J Cancer Prev; 2018 Aug; 19(8):2057-2070. PubMed ID: 30139042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Advance in studies on natural antidepressant drugs and cytochrome P450].
    Zhang L; Wang FH; Chen SZ; Pan JC
    Zhongguo Zhong Yao Za Zhi; 2015 Mar; 40(5):828-32. PubMed ID: 26087541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I and Phase II enzyme polymorphisms and childhood cancer.
    Swinney R; Hsu S; Tomlinson G
    J Investig Med; 2006 Sep; 54(6):303-20. PubMed ID: 17134614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.
    Ingelman-Sundberg M
    Trends Pharmacol Sci; 2004 Apr; 25(4):193-200. PubMed ID: 15063083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy.
    Gong L; Zhang CM; Lv JF; Zhou HH; Fan L
    Pharmacogenet Genomics; 2017 Sep; 27(9):337-346. PubMed ID: 28731962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytochrome P450 polymorphisms as risk factors for steroid hormone-related cancers.
    Friedberg T
    Am J Pharmacogenomics; 2001; 1(2):83-91. PubMed ID: 12174676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of cancer susceptibility in humans by use of genetic polymorphisms in carcinogen metabolism.
    Ikawa S; Uematsu F; Watanabe K; Kimpara T; Osada M; Hossain A; Sagami I; Kikuchi H; Watanabe M
    Pharmacogenetics; 1995; 5 Spec No():S154-60. PubMed ID: 7581487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Applications of AmpliChip CYP450.
    Jain KK
    Mol Diagn; 2005; 9(3):119-27. PubMed ID: 16271013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Individuality in cytochrome P450 expression and its association with the nephrotoxic and carcinogenic effects of chemicals.
    Wolf CR
    IARC Sci Publ; 1991; (115):281-7. PubMed ID: 1820342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical significance of some genetic polymorphisms of cytochrome P-450: family CYP1 and subfamilies CYP2A, CYP2B and CYP2C].
    Wojtczak A; Skretkowicz J
    Pol Merkur Lekarski; 2009 Mar; 26(153):248-52. PubMed ID: 19388543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.
    Sim SC; Kacevska M; Ingelman-Sundberg M
    Pharmacogenomics J; 2013 Feb; 13(1):1-11. PubMed ID: 23089672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of drug-metabolizing enzyme hydroxylation phenotypes in Hispanic populations: the CEIBA cocktail.
    de Andrés F; Sosa-Macías M; Lazalde-Ramos BP; Naranjo ME; Tarazona-Santos E; Llerena A;
    Drug Metabol Drug Interact; 2013; 28(3):135-46. PubMed ID: 23787463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics.
    Deeken JF; Figg WD; Bates SE; Sparreboom A
    Anticancer Drugs; 2007 Feb; 18(2):111-26. PubMed ID: 17159598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer therapy and polymorphisms of cytochromes P450.
    MacLeod SL; Nowell S; Massengill J; Jazieh A; McClure G; Plaxco J; Kadlubar FF; Lan NP
    Clin Chem Lab Med; 2000 Sep; 38(9):883-7. PubMed ID: 11097344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical significance of cytochrome P450 genetic polymorphism--part I. Enzymatic system of cytochrome P450 and cytochrome P450 1A2].
    Duricová J; Grundmann M
    Ceska Slov Farm; 2011 Jun; 60(3):110-5. PubMed ID: 21838140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chapter 21. Additional polymorphisms and cancer.
    Stubbins MJ; Wolf CR
    IARC Sci Publ; 1999; (148):271-302. PubMed ID: 10493263
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacogenomics. What is relevant for the internal medicine specialist?].
    Krüth P; Wehling M
    Internist (Berl); 2003 Dec; 44(12):1524-30. PubMed ID: 14689195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of cytochrome P-450 genetic polymorphisms in oral carcinogenesis.
    Hernando-Rodriguez M; Rey-Barja N; Marichalar-Mendia X; Rodriguez-Tojo MJ; Acha-Sagredo A; Aguirre-Urizar JM
    J Oral Pathol Med; 2012 Jan; 41(1):1-8. PubMed ID: 21793938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Relationship between the gene polymorphisms of oxidative metabolism enzyme of exogenous chemicals and the susceptibility to neoplasms].
    Xia G; Hu J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Dec; 42(12):1439-1446. PubMed ID: 29317586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic polymorphism and toxicology--with emphasis on cytochrome p450.
    Johansson I; Ingelman-Sundberg M
    Toxicol Sci; 2011 Mar; 120(1):1-13. PubMed ID: 21149643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.